Cargando…
Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies
Chimeric antigen receptor (CAR) T-cell therapy has made remarkable progress in cancer immunotherapy, but several challenges with unclear mechanisms hinder its wide clinical application. Single-cell sequencing technologies, with the powerful unbiased analysis of cellular heterogeneity and molecular p...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163813/ https://www.ncbi.nlm.nih.gov/pubmed/37149643 http://dx.doi.org/10.1186/s12943-023-01783-1 |
_version_ | 1785037961989980160 |
---|---|
author | Huang, Shengkang Wang, Xinyu Wang, Yu Wang, Yajing Fang, Chenglong Wang, Yazhuo Chen, Sifei Chen, Runkai Lei, Tao Zhang, Yuchen Xu, Xinjie Li, Yuhua |
author_facet | Huang, Shengkang Wang, Xinyu Wang, Yu Wang, Yajing Fang, Chenglong Wang, Yazhuo Chen, Sifei Chen, Runkai Lei, Tao Zhang, Yuchen Xu, Xinjie Li, Yuhua |
author_sort | Huang, Shengkang |
collection | PubMed |
description | Chimeric antigen receptor (CAR) T-cell therapy has made remarkable progress in cancer immunotherapy, but several challenges with unclear mechanisms hinder its wide clinical application. Single-cell sequencing technologies, with the powerful unbiased analysis of cellular heterogeneity and molecular patterns at unprecedented resolution, have greatly advanced our understanding of immunology and oncology. In this review, we summarize the recent applications of single-cell sequencing technologies in CAR T-cell therapy, including the biological characteristics, the latest mechanisms of clinical response and adverse events, promising strategies that contribute to the development of CAR T-cell therapy and CAR target selection. Generally, we propose a multi-omics research mode to guide potential future research on CAR T-cell therapy. |
format | Online Article Text |
id | pubmed-10163813 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-101638132023-05-07 Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies Huang, Shengkang Wang, Xinyu Wang, Yu Wang, Yajing Fang, Chenglong Wang, Yazhuo Chen, Sifei Chen, Runkai Lei, Tao Zhang, Yuchen Xu, Xinjie Li, Yuhua Mol Cancer Review Chimeric antigen receptor (CAR) T-cell therapy has made remarkable progress in cancer immunotherapy, but several challenges with unclear mechanisms hinder its wide clinical application. Single-cell sequencing technologies, with the powerful unbiased analysis of cellular heterogeneity and molecular patterns at unprecedented resolution, have greatly advanced our understanding of immunology and oncology. In this review, we summarize the recent applications of single-cell sequencing technologies in CAR T-cell therapy, including the biological characteristics, the latest mechanisms of clinical response and adverse events, promising strategies that contribute to the development of CAR T-cell therapy and CAR target selection. Generally, we propose a multi-omics research mode to guide potential future research on CAR T-cell therapy. BioMed Central 2023-05-06 /pmc/articles/PMC10163813/ /pubmed/37149643 http://dx.doi.org/10.1186/s12943-023-01783-1 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Review Huang, Shengkang Wang, Xinyu Wang, Yu Wang, Yajing Fang, Chenglong Wang, Yazhuo Chen, Sifei Chen, Runkai Lei, Tao Zhang, Yuchen Xu, Xinjie Li, Yuhua Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies |
title | Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies |
title_full | Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies |
title_fullStr | Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies |
title_full_unstemmed | Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies |
title_short | Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies |
title_sort | deciphering and advancing car t-cell therapy with single-cell sequencing technologies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163813/ https://www.ncbi.nlm.nih.gov/pubmed/37149643 http://dx.doi.org/10.1186/s12943-023-01783-1 |
work_keys_str_mv | AT huangshengkang decipheringandadvancingcartcelltherapywithsinglecellsequencingtechnologies AT wangxinyu decipheringandadvancingcartcelltherapywithsinglecellsequencingtechnologies AT wangyu decipheringandadvancingcartcelltherapywithsinglecellsequencingtechnologies AT wangyajing decipheringandadvancingcartcelltherapywithsinglecellsequencingtechnologies AT fangchenglong decipheringandadvancingcartcelltherapywithsinglecellsequencingtechnologies AT wangyazhuo decipheringandadvancingcartcelltherapywithsinglecellsequencingtechnologies AT chensifei decipheringandadvancingcartcelltherapywithsinglecellsequencingtechnologies AT chenrunkai decipheringandadvancingcartcelltherapywithsinglecellsequencingtechnologies AT leitao decipheringandadvancingcartcelltherapywithsinglecellsequencingtechnologies AT zhangyuchen decipheringandadvancingcartcelltherapywithsinglecellsequencingtechnologies AT xuxinjie decipheringandadvancingcartcelltherapywithsinglecellsequencingtechnologies AT liyuhua decipheringandadvancingcartcelltherapywithsinglecellsequencingtechnologies |